RESUMEN
To overcome the limitations of the state-of-the-art influenza surveillance systems in Europe, we established in 2008 a European-wide consortium aimed at introducing an innovative information and communication technology approach for a web-based surveillance system across different European countries, called Influenzanet. The system, based on earlier efforts in The Netherlands and Portugal, works with the participation of the population in each country to collect real-time information on the distribution of influenza-like illness cases through web surveys administered to volunteers reporting their symptoms (or lack of symptoms) every week during the influenza season. Such a large European-wide web-based monitoring infrastructure is intended to rapidly identify public health emergencies, contribute to understanding global trends, inform data-driven forecast models to assess the impact on the population, optimize the allocation of resources, and help in devising mitigation and containment measures. In this article, we describe the scientific and technological issues faced during the development and deployment of a flexible and readily deployable web tool capable of coping with the requirements of different countries for data collection, during either a public health emergency or an ordinary influenza season. Even though the system is based on previous successful experience, the implementation in each new country represented a separate scientific challenge. Only after more than 5 years of development are the existing platforms based on a plug-and-play tool that can be promptly deployed in any country wishing to be part of the Influenzanet network, now composed of The Netherlands, Belgium, Portugal, Italy, the UK, France, Sweden, Spain, Ireland, and Denmark.
Asunto(s)
Monitoreo Epidemiológico , Gripe Humana/epidemiología , Gripe Humana/prevención & control , Internet , Vigilancia en Salud Pública , Investigación Participativa Basada en la Comunidad , Brotes de Enfermedades/estadística & datos numéricos , Europa (Continente)/epidemiología , Encuestas Epidemiológicas , HumanosRESUMEN
The effectiveness of influenza vaccination programmes is seldom known during an epidemic. We developed an internet-based system to record influenza-like symptoms and response to infection in a participating cohort. Using self-reports of influenza-like symptoms and of influenza vaccine history and uptake, we estimated vaccine effectiveness (VE) without the need for individuals to seek healthcare. We found that vaccination with the 2010 seasonal influenza vaccine was significantly protective against influenza-like illness (ILI) during the 2010-2011 influenza season (VE 52%, 95% CI 27-68). VE for individuals who received both the 2010 seasonal and 2009 pandemic influenza vaccines was 59% (95% CI 27-77), slightly higher than VE for those vaccinated in 2010 alone (VE 46%, 95% CI 9-68). Vaccinated individuals with ILI reported taking less time off work than unvaccinated individuals with ILI (3.4 days vs. 5.3 days, P<0.001).
Asunto(s)
Vacunas contra la Influenza/administración & dosificación , Vacunas contra la Influenza/inmunología , Gripe Humana/prevención & control , Absentismo , Adolescente , Adulto , Anciano de 80 o más Años , Niño , Preescolar , Estudios de Cohortes , Recolección de Datos/métodos , Femenino , Humanos , Lactante , Recién Nacido , Gripe Humana/patología , Internet , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
The unfolding of pandemic influenza A(H1N1) for Fall 2009 in the Northern Hemisphere is still uncertain. Plans for vaccination campaigns and vaccine trials are underway, with the first batches expected to be available early October. Several studies point to the possibility of an anticipated pandemic peak that could undermine the effectiveness of vaccination strategies. Here, we use a structured global epidemic and mobility metapopulation model to assess the effectiveness of massive vaccination campaigns for the Fall/Winter 2009. Mitigation effects are explored depending on the interplay between the predicted pandemic evolution and the expected delivery of vaccines. The model is calibrated using recent estimates on the transmissibility of the new A(H1N1) influenza. Results show that if additional intervention strategies were not used to delay the time of pandemic peak, vaccination may not be able to considerably reduce the cumulative number of cases, even when the mass vaccination campaign is started as early as mid-October. Prioritized vaccination would be crucial in slowing down the pandemic evolution and reducing its burden.
RESUMEN
The case of a 73-year-old man with metastatic small cell carcinoma (SCC) of the prostate is described. Seric neuron-specific enolase (NSE) was enhanced (75.4 ng/mL), while the prostate-specific antigen (PSA) was in the normal range. Therapy with etoposide and carboplatin induced a temporary partial remission, with fairly good quality of life and decrease of the NSE levels (down to 15.0 ng/mL). The patient died approximately 12 months after the initial diagnosis. The case confirms that prostatic SCC (a rare and very aggressive neoplasm) is usually diagnosed in an advanced stage. Treatment is problematic, however chemotherapy may prolong survival allowing, at least temporarly, an acceptable life quality. NSE measurement is useful to differentiate SCC from the more common adenocarcinoma (typically associated with elevated PSA values) and for follow-up.
Asunto(s)
Carcinoma de Células Pequeñas/patología , Neoplasias de la Próstata/patología , Anciano , Biomarcadores de Tumor/sangre , Antígeno Carcinoembrionario/sangre , Carcinoma de Células Pequeñas/sangre , Carcinoma de Células Pequeñas/secundario , Resultado Fatal , Femenino , Humanos , Neoplasias Pulmonares/secundario , Masculino , Fosfopiruvato Hidratasa/sangre , Pronóstico , Neoplasias de la Próstata/sangre , Neoplasias Cutáneas/secundarioRESUMEN
The vesicular monoamine transporter 2 (VMAT2) facilitates the ATP-dependent accumulation of biogenic amine inside the secretory granules of endocrine cells and neurons and was demonstrated in the histamine-producing enterochromaffin-like (ECL) cells of the stomach. In the present investigation, VMAT2 immunohistochemistry was tested in 85 endocrine tumors, of which 60 were well differentiated gastrointestinal and pancreatic growths, 5 poorly differentiated (neuro)endocrine carcinomas (PDEC) and 1 mixed PDEC/ECL cell carcinoma of the stomach, 12 pheochromocytomas/paragangliomas, 3 adrenocortical lesions, 2 parathyroid and 2 lung neuroendocrine tumors. Extensive and intense VMAT2 immunoreactivity was observed in 16 of 16 gastric ECL cell tumors, 6 of 6 adrenal pheochromocytomas, 2 of 2 chromaffin paragangliomas and in 3 of the 4 carotid body paragangliomas investigated. Rare VMAT2-positive cells were observed in 12 of 21 intestinal enterochromaffin (EC) cell tumors, in 9 of 11 pancreatic neuroendocrine tumors, and in the mixed PDEC/ ECL cell carcinoma of the stomach (differentiated cells only). No VMAT2 immunoreactivity was observed in five gastrin, four somatostatin and three enteroglucagon/peptideYY tumors of the gastrointestinal tract, in six gastric PDECs, in three adrenocortical growths, and two parathyroid and two lung neuroendocrine tumors. These data support VMAT2 immunohistochemistry as being a useful tool for the diagnosis of gastric ECL cell tumors, separating them from all other endocrine tumors arising in the gastroduodenal area i.e., gastrin, somatostatin, EC cell and PDEC tumors, all of which proved essentially negative.
Asunto(s)
Biomarcadores de Tumor , Células Similares a las Enterocromafines/metabolismo , Células Similares a las Enterocromafines/patología , Glicoproteínas de Membrana/metabolismo , Proteínas de Transporte de Membrana , Neuropéptidos , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/patología , Humanos , Inmunohistoquímica , Proteínas de Transporte Vesicular de Aminas Biógenas , Proteínas de Transporte Vesicular de MonoaminasRESUMEN
Recent developments in the field of endocrine cell biology and pathology, at both morphologic and molecular levels, are briefly outlined and discussed as a basis for endocrine tumour characterization. The main clinicopathological tools available for the identification and characterization of endocrine tumours are discussed. Based on this, classifications of endocrine tumours of the pancreas and gastrointestinal tract are developed covering most clinical (hyperfunctional syndromes included), pathologic and biological patterns and with special emphasis on tumour prognosis.
Asunto(s)
Neoplasias de las Glándulas Endocrinas/clasificación , Neoplasias de las Glándulas Endocrinas/patología , Neoplasias Gastrointestinales/clasificación , Neoplasias Gastrointestinales/patología , Neoplasias Pancreáticas/clasificación , Neoplasias Pancreáticas/patología , Neoplasias de las Glándulas Endocrinas/genética , Neoplasias Gastrointestinales/genética , Humanos , Neoplasias Pancreáticas/genéticaRESUMEN
BACKGROUND & AIMS: Gastric endocrine tumors show a wide spectrum of clinical behavior, and prognostic assessement of individual tumors is difficult. The aims of this work were to identify predictors of tumor malignancy and patient outcome and to provide a rationale for treatment guidelines. METHODS: Gastric endocrine tumors (86 enterochromaffin-like cell carcinoids and 16 poorly differentiated carcinomas) were investigated for 15 clinicopathologic variables and for expression of Ki67, P53, and BCL-2 proteins. Data were analyzed by univariate and multivariate statistics for evidence of tumor malignancy and patient survival. RESULTS: Histological grades 2 and 3, size >/=3 cm, 9 or more mitoses, or >/=300 Ki67-positive cells per 10 high-power fields identified 26 of 33 (79%) malignant (metastatic or deeply invasive) tumors, and size <1 cm and/or growth restricted to the mucosa characterized 46 of 69 (67%) tumors with benign behavior during a median follow-up of 39 months. Malignancy-predictive models were developed using angioinvasion, size, clinicopathologic type, mitotic index, and Ki67 index. The same variables, in addition to deep gastric wall invasion and histological grade, predicted patient outcome. CONCLUSIONS: Criteria for the assessment of malignancy risk and patient outcome were developed for the different tumors, providing a basis for treatment guidelines.
Asunto(s)
Tumor Carcinoide/patología , Carcinoma/patología , Neoplasias Gástricas/patología , Análisis de Varianza , Tumor Carcinoide/clasificación , Tumor Carcinoide/mortalidad , Carcinoma/clasificación , Carcinoma/mortalidad , Femenino , Mucosa Gástrica/patología , Gastritis/patología , Humanos , Antígeno Ki-67/análisis , Metástasis Linfática , Masculino , Persona de Mediana Edad , Índice Mitótico , Análisis Multivariante , Invasividad Neoplásica , Neovascularización Patológica , Guías de Práctica Clínica como Asunto , Pronóstico , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Análisis de Regresión , Estudios Retrospectivos , Neoplasias Gástricas/clasificación , Neoplasias Gástricas/mortalidad , Tasa de Supervivencia , Factores de Tiempo , Proteína p53 Supresora de Tumor/análisisRESUMEN
Tumours of the endocrine pancreas are rare entities with evidence of endocrine cell differentiation. Immunohistochemistry is the most reliable method used to study such tumours either for the identification of their hormonal product(s) or to explore functional aspects like proliferative activity or oncoprotein overexpression (e.g. p53). Most of the endocrine tumours of the pancreas are well differentiated and behave as benign or low grade malignant tumours. Poorly differentiated (small cell) endocrine carcinomas are rare and have a poor prognosis.
Asunto(s)
Neoplasias Pancreáticas/patología , Humanos , Islotes Pancreáticos/citología , Páncreas/citologíaRESUMEN
A series of 50 gastric endocrine tumors classified according to Rindi et al. [1] comprised 12 small cell neuroendocrine carcinomas (NEC) and 38 ECL cell carcinoids, of which 22 associated with type A chronic atrophic gastritis (A-CAG), eight with hypertrophic gastropathy due to combined Multiple Endocrine Neoplasia and Zollinger/Ellison syndrome (MEN/ZES), and eight sporadic. Variables found to predict tumor malignancy were: size > 2 cm, > 2 mitoses and > 130 Ki67 positive cells/10 high power fields (HPF), grade 2 or 3 histology, angioinvasion, p53 protein nuclear accumulation, and the presence of a single tumor. None of these factors increased significantly the predicting ability of tumor classification itself, although grade 2 + 3 shows 100 percent negative predictive value and Ki67 and angioinvasion 100 percent positive predictive value. When the mostly non-malignant A-CAG and MEN-ZES tumors were analysed against the mostly malignant sporadic and NEC tumors, a positive predictive value of 90 percent and a negative predictive value of 93 percent was obtained. Investigation of a larger tumor series is under way with the aim to develop an optimal model for prognostic evaluation of gastric endocrine tumors.